CoChat

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Open access
Hariprasad, Seenu M., Morse, Lawrence S., Shapiro, Howard, Wong, Pamela, Tuomi, Lisa · 2012 · Journal of Ophthalmology

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response.Design. Retrospective analysis.Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed.Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7–16.1%) than with less frequent dosing (5.0–6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted.Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2012/690641

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overall mean change in visual acuity (VA) over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.
Figure 1 Overall mean change in visual acuity (VA) over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.CC BY · PubMed Central
Figure 2 Distribution of visual acuity change from baseline based on visual acuity status at month 3 among pooled ranibizumab-treated patients by clinical trial. aAll visual acuity changes are compared with baseline. For ease of interpretation, all percentages are rounded to the nearest whole number.
Figure 2 Distribution of visual acuity change from baseline based on visual acuity status at month 3 among pooled ranibizumab-treated patients by clinical trial. aAll visual acuity changes are compared with baseline. For ease of interpretation, all percentages are rounded to the nearest whole number.CC BY · PubMed Central
Figure 3 Time to first gain of ≥15 letters from baseline among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.
Figure 3 Time to first gain of ≥15 letters from baseline among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.CC BY · PubMed Central
Figure 4 Percentage of patients gaining ≥15 letters from baseline over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.
Figure 4 Percentage of patients gaining ≥15 letters from baseline over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively.CC BY · PubMed Central
Figure 5 Percentage of patients with 20/40 or better vision over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively. ANCHOR: n = 279 at month 0; SAILOR cohort 1 treatment-naïve: n = 946 at month 0.
Figure 5 Percentage of patients with 20/40 or better vision over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively. ANCHOR: n = 279 at month 0; SAILOR cohort 1 treatment-naïve: n = 946 at month 0.CC BY · PubMed Central
Figure 6 Percentage of patients with 20/200 or worse vision over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively. ANCHOR: n = 279 at month 0; SAILOR cohort 1 treatment-naïve: n = 946 at month 0.
Figure 6 Percentage of patients with 20/200 or worse vision over time among pooled ranibizumab-treated patients by clinical trial. Dosing: ANCHOR and MARINA, monthly; PIER, months 0, 1, 2, 5, 8, 11, 14, 17, 20, and 23; SAILOR, months 0, 1, and 2, then as needed. Vertical line indicates switch from monthly to quarterly and as-needed dosing in PIER and SAILOR, respectively. ANCHOR: n = 279 at month 0; SAILOR cohort 1 treatment-naïve: n = 946 at month 0.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 2012, Journal of Clinical and Experimental Ophthalmology, 3, 221

Cited by

See all 21

Metadata

Authors
Hariprasad, S. M., Morse, L. S., Shapiro, H., Wong, P., & Tuomi, L.
Affiliations
  • University of Chicago (US)
  • University of California Davis Medical Center (US)
  • Genentech (US)
Corresponding author
Hariprasad, Seenu M.
Venue
Journal of Ophthalmology
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-8
ISSN
  • 2090-004X (ISSN-L)
  • 2090-0058
OpenAlex
W2140544410
Cited by
20
References
13
Citations by year
2024: 2 · 2023: 1 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 6 · 2015: 4 · 2013: 1
FWCI
1.50
Type
journal article
Language
en
Open access
Locations
  • Journal of Ophthalmology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ranibizumab, neovascular age-related macular degeneration, dosing frequency, monthly dosing, as-needed dosing, loading dose, ANCHOR trial, MARINA trial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.